The specificity, efficacy and safety profiles of biologics make them good candidates for the treatment of autoimmune diseases, and the significant unmet medical needs in both large and orphan indications makes this an attractive field of research for industry companies. Scientists are striving to identify novel targets and mechanisms of action, and to apply exciting new product platforms and technologies in this space.  But major challenges remain in the areas of demonstrating improved efficacy over established standards of care, identifying quality preclinical research models and stratifying responder populations to improve clinical studies and applications. The 3rd Annual Biologics for Autoimmune Diseases presents a focused meeting that explores the application of new science and technology in the development of a next generation of effective and safe therapeutics in autoimmunity and inflammation. 


Complement-Targeted Biotherapeutics for Autoimmune Diseases

Uday Kishore, Ph.D., Director, Center for Infection, Immunity and Disease Mechanisms, Brunel University, United Kingdom


Venom-Derived Peptides for the Treatment of Autoimmune Disease

Christine Beeton, Ph.D., Associate Professor, Molecular Physiology and Biophysics, Baylor College of Medicine

Novel Mechanisms of Action for Inhibitory Receptors as Targets for Autoimmune Indications

Ali Zarrin, Ph.D., Scientist, Immunology, Genentech, Inc.

“Accelerating” Discoveries in Autoimmunity

PJ Utz, M.D., Professor, Immunology and Rheumatology, Stanford University School of Medicine

Investigation of Antibody-Drug Conjugates as Therapeutics for Autoimmune Diseases

Phil Brandish, Ph.D., Principal Scientist, Merck


New Diseases for Old Tools, Different Approaches to Known Targets: Expanding Indications for Approved Biologics into Rare Diseases

John H. Stone, M.D., MPH, The Edward Fox Chair in Medicine, Massachusetts General Hospital; Professor, Medicine, Harvard Medical School (Case Study)

Clinical Studies of Biologics in Autoimmune Diseases and How These Can Inform Applications in Secondary Indications

Jeffrey Siegel, M.D., Senior Group Medical Director, Product Development Immunology Genentech, Inc.

Deep Biocharacterization of Autoimmune Disease Patients Yields Unique Insights into Unmet Medical Need

Tony Manning, Ph.D., Vice President, Research, Momenta Pharmaceuticals

TH17 Targets for Multiple Autoimmune Diseases

Andrea Itano, Ph.D., Vice President, Head of Tempero Discovery Performance Unit, Immuno-Inflammation, GlaxoSmithKline

Antigen Specific Regulatory T Cells (Ag-Tregs) for Inflammatory and Autoimmune Diseases

Arnaud Foussat, Ph.D., Chief Scientific Officer, TxCell, France


Investigation and Mitigation of Safety Issues in Autoimmune Disease Biologics

Meena Subramanyam, Ph.D., Vice President, Translational Sciences & Technology, Biogen

Sjögren’s Manifestations in Aged Mice Arise from Early Life Immune Dysregulation

Rachel Ettinger, Ph.D., Senior Scientist Respiratory, Inflammatory, and Autoimmune Diseases, MedImmune

Potent Neutralizing Anti-CD1d Antibody Reduces Lung Cytokine Release in Primate Asthma Model

Adam Clarke, Ph.D., Director, Lead Generation, Teva Pharmaceuticals, Australia

Dissecting the Properties of Anti-CXCL10 Antibodies Having Anti-Inflammatory Activity In Vivo

Nicolas Fischer, Ph.D., Head of Research, Novimmune, France

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199

Jason Gerardi
(Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452

Carol Dinerstein
(Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471